Drug Trial Radar · NCT03453528
Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,225
Actual
Start
Jul 4, 2017
Primary completion
Dec 4, 2024
Study completion Jan 3, 2025
Sponsor
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
multi-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer (mCRPC) and in advanced/metastatic solid tumors patients.
Conditions
- Prostate-specific Membrane Antigen
- mCRPC or Advanced/Metastatic Solid Tumors
Interventions
68Ga-PSMADrug
68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- detection rate of 68Ga-PSMA PET/CTTime frame: up to 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
Meldola, FC, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.